The group of disorders that involves loss of previously established memories, loss of ability to generate new memories or loss of ability to learn new information.  The amnestic disorders may occur due to general medical conditions that results in memory disturbances and exposure to certain chemicals like medications, drug of abuse or environmental toxin. Amnestic disorders are caused by chemical or structural damage to the parts of brain.

Structural damage to the parts of brain can be caused due to head injury or trauma, stroke, tumors or cerebrovascular diseases. Chemical changes in the brain can be a result of long-term heavy drug use, excessive intake of alcohol, exposure to toxins such as mercury, lead, carbon monoxide, and certain insecticides. There are main three types of amnesia namely anterograde amnesia, retrograde amnesia and transient global amnesia. Anterograde amnesia is the form of amnesia which occurs due to brain trauma and is characterized by the inability to remember new information. In anterograde amnesia, victims can recall memories and events prior to trauma, however recent experiences and short-term memory disappear.

In retrograde amnesia, the memories after the trauma can be recalled but events before the trauma can’t be remembered. In the third form of amnesia i.e. the transient global amnesia, victim experiences sudden forgetfulness and confusions. There is no identifiable cause for transient global amnesia, but researchers have found that migraines or transient ischemic attacks may trigger this. Transient global amnesia usually has an excellent prognosis for recovery.

Identify the key factors that will drive your company’s growth, Request a brochure of this report here

Amnestic Disorders Therapeutics Market – Competitive Landscape

The global amnestic disorders therapeutics market comprises of large and mid-size vendors. Key players in amnestic disorders therapeutics market include Allergan plc, Troikaa Pharmaceuticals Ltd., Zydus Cadila, Neon Laboratories Limited, Johnson & Johnson, Janssen Pharmaceuticals, Novartis International AG and Merz Pharma GmbH & Co. KGaA,

Novartis AG

Novartis AG is a global healthcare company that develops and provides solutions to the changing needs of patients, worldwide. The company was established in 1996 through a merger of Ciba-Geigy and Sandoz. Presently, it operates through three primary areas: innovative patented medicines (pharmaceuticals), eye care devices (Alcon), and generics (Sandoz). Its innovative medicines segment has two business units: Novartis Pharmaceuticals and Novartis Oncology. Novartis Pharmaceuticals operates multiple categories including neuroscience.

Allergan plc

Allergan plc. engages in the development, manufacture, and commercialization of branded pharmaceuticals, devices, and biologic products. The company’s products cater to diverse therapy areas including central nervous system, ophthalmology, medical aesthetics, gastroenterology, women health, urology, cardiovascular, and anti-infectives.

Merz Pharma GmbH & Co. KGaA

Merz Pharma engages in the development, research, and sale of innovative medical drugs and products for neurological and clinical dermatological purposes. The company operates in the market through its aesthetics and neurotoxins products, which are driving the company towards innovation and strategic acquisitions.

Rising Prevalence of Amnesia will fuel the Amnestic Disorders Therapeutics Market

The global amnestic disorders therapeutics market is subjected to grow during the forecast period. The overall incidence of the amnestic disorders is increasing across the world. According to an article published by National Center for Biotechnology Information, the incidence rate of transient global amnesia (TGA) is around 5.2-10/100,000 per year in the general population. In individuals aged 50 and above, the incidence rate increases to 23.5 to 32/100,000 per year. Majority of the cases have been reported in patients aged 50 to 80 years old.

The global population is aging rapidly. Increasing geriatric population has been the main driver of the amnestic disorders therapeutics market.  According to the WHO, nearly 2 billion people are expected to be aged 60 and above by 2050, accounting for nearly 16.7% of the global population. The population in developed countries such as those in Western Europe, Japan, and the U.S. is aging at a high rate. Some reasons behind it are better health care infrastructure and adoption of advanced medical techniques.

Expanding operations in future? To get the perfect launch ask for a custom report here

High Diagnosis Rate and Rising Disposable Income to boost the Amnestic Disorders Therapeutics Market

Access to various diagnostic and treatment services has improved in developed as well as developing economies in the past few years. This, in turn, has increased the life expectancy of the overall population. North America is expected to account for the highest share of the amnestic disorders therapeutics market in terms of revenue followed by Europe. These two regions are expected to retain their leadership positions throughout the forecast period.

The superiority of these two regions is majorly due to high diagnosis rate, high disposable income, favorable reimbursement scenario, presence of a large number of hospitals and well developed healthcare infrastructure. China and India are the major markets in Asia Pacific that offer large opportunities for the amnestic disorders therapeutics market.  The amnestic disorders therapeutics market in Asia Pacific is projected to expand at the highest CAGR compared to other regions. Expanding health care infrastructure, rising disposable income, and increasing geriatric population are some of the factors that are expected to play a key role in making Asia Pacific the most attractive market.

Amnestic Disorders Therapeutics Market – Segmentation

On the basis of drug type, amnestic disorders therapeutics market is segmented into:

  • Cholinesterase inhibitors
    • donepezil
    • rivastigmine
    • galantamine
    • others
  • Memantine

Based on distribution channel, the amnestic disorders therapeutics market is categorized into:

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies.

The report on amnestic disorders therapeutics market is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The amnestic disorders therapeutics market report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The amnestic disorders therapeutics market report also maps the qualitative impact of various market factors on market segments and geographies.

Regional Analysis For Amnestic Disorders Therapeutics Market Include:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Amnestic Disorders Therapeutics Market

Pre Book